Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760350 | 1.00 | RET (0.55) | RETGPR119TLR7TLR8TLR9 | |
| SCHEMBL29760322 | 0.86 | TLR8 (0.62) | TLR7TLR8TLR9JAK2 | |
| SCHEMBL23165728 | 0.86 | TLR8 (0.62) | TLR7TLR8TLR9JAK2 | |
| SCHEMBL29760283 | 0.83 | TLR8 (0.63) | TLR7TLR8TLR9 | |
| SCHEMBL23165999 | 0.83 | TLR8 (0.63) | TLR7TLR8TLR9 | |
| SCHEMBL23166914 | 0.82 | TLR7 (0.52) | RETTLR7TLR8TLR9JAK2 | |
| SCHEMBL29760375 | 0.82 | TLR7 (0.52) | RETTLR7TLR8TLR9JAK2 | |
| SCHEMBL23166000 | 0.82 | GPR119 (0.53) | GPR119TLR7TLR8TLR9JAK2 | |
| SCHEMBL23165892 | 0.80 | CNR1 (0.46) | RETGPR119LRRK2 | |
| SCHEMBL29760337 | 0.80 | CNR1 (0.46) | RETGPR119LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384760-B2 | Substituted carbazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-12 | — | — | US | disclosed |
| CN-114829350-B | Substituted carbazole compounds | 百时美施贵宝公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240076280-A1 | SUBSTITUTED CARBAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-03-07 | — | — | US | disclosed |
| EP-4038059-B1 | SUBSTITUTED CARBAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4038059-B1 | SUBSTITUTED CARBAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4038059-A1 | SUBSTITUTED CARBAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114829350-A | Substituted carbazole compounds | 百时美施贵宝公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021067657-A1 | SUBSTITUTED CARBAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067657-A1 | SUBSTITUTED CARBAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076280-A1 | SUBSTITUTED CARBAZOLE COMPOUNDS | TLR7, TLR3, TLR1 | RET 303/4885GPR119 60/4885TLR7 1/4885 |
| US-12384760-B2 | Substituted carbazole compounds | TLR7, TLR3, TLR1 | RET 303/4885GPR119 60/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.